Lp-PLA2 is also known as platelet-activating factor acetylhydrolase (PAF-AH). The molecular weight is 45KDa. It is synthesized and secreted by mature macrophages and lymphocytes, and is regulated by inflammatory mediators. It hydrolyzes the phospholipids of low-density lipoproteins to produce pro-inflammatory substances lysolecithin and oxidized fatty acids, so it has the effect of promoting inflammation and promoting atherosclerosis.
Lp-PLA2 is an independent cardiovascular disease risk predictor and is not affected by other biological indicators. It also provides new evidence for the link between inflammation, atherosclerosis, and cardiovascular disease.[1]
Product Specification
|
Specimen Types |
WB/Plasma/Serum |
|
Specimen Capacity |
WB:15μL; Plasma/Serum:10μL |
|
Reaction Time |
10 min |
|
Sample Capacity |
80μL |
|
Detection Range |
5-800.0ng/mL |
Simple operation and fast response (10min)
✔ Markers of vascular endothelial inflammation
✔ Initiated in the early stages of the vascular inflammation process
✔ Not affected by other inflammatory diseases
✔ It is a specific target for drug intervention and treatment of coronary heart disease
ICU, Respiratory Medicine, Cardiology
Reference
1.The Lp-PLA2 Studies Collaboration, Lancet 2010; 375: 1536–44.
Gold supplier
Facebook 
Twitter 
Linkedin 
YouTube 
Blogger 
Instagram 
